Genome and Company has acquired a majority stake in Scioto Biosciences following its contribution to a series B round that will be sized at up to $26.5m.
Scioto Biosciences, a US-based developer of brain and bowel disease treatments, has secured up to $26.5m in series B funding from investors including microbiome therapeutics provider Genome and Company, it announced yesterday.
The unnamed additional investors will provide their share of the round in a later tranche, and Genome and Company has acquired a majority stake of undisclosed size through the transaction.
Founded in 2017, Scioto is working on treatments that will utilise beneficial bacteria colonisation in the gut to…
